Related Experiment Video
Updated: Aug 7, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component
T Monif1, S K Tippabhotla, M Garg
1Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories Ltd., Gurgaon, Haryana, India. tausif.monif@ranbaxy.com
Objective:
The objective of the study was to compare the bioequivalence of a fixed-dose combination of a nevirapine 200 mg, lamivudine 150 mg and stavudine 30 mg combination tablet with application of the 3 medications, at the same dosage, concurrently as separate formulations, in healthy, adult subjects under fasting conditions.
Material And Methods:
An open-label, balanced, randomized, 2-treatment, 2-period, 2-sequence, single-dose, crossover bioavailability study was conducted in 40 subjects with 21-day washout period between each treatment. Blood samples were collected for 168 hours. Plasma concentrations of nevirapine, lamivudine and stavudine were determined using a validated LC-MS-MS method. Noncompartmental pharmacokinetics and statistical analyses were performed using SAS (SAS Institute Inc., Cary, NC, USA) software (SAS System under Windows, Version 8.02).
Results:
The ratios of least-square means and the 90% confidence intervals of the log-transformed data were calculated for AUC(0-t), AUC(0-inf), and Cmax. The 90% confidence interval for least-square mean ratio between test and reference formulation for log-transformed parameters Cmax, AUC(0-t) and AUC(0-inf) were within the requirements of the 80-125% range.
Conclusion:
The test formulation (Ranbaxy Laboratories Ltd., Gurgaon, India) is bioequivalent to the reference formulations both in terms of rate and extent of absorption after single-dose administration under fasting condition.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Bioequivalence studies: Biowaivers
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Study Design: Healthy Subjects Versus Patients

